Abstract
Ovotransferrin as a novel drug-targeting molecule for cancer chemotherapy
Highlights
Cancer is as a result of the unregulated growth of cancer cells because it lost the normal regulatory mechanisms that control cell growth and become insensitive to growth inhibitory signals
The results suggest that the transferrin receptor (TfR) can be targeted by conjugation of anticancer drugs to OTf that is recognized by TfR on cancer cells
The results suggest that the OTf-drug conjugates induce inhibition of cells growth of HCT-116 and MCF-7 and it seems that the low drug loading of OTf in the conjugate (3 moles drug/OTf mole) is the most effective against both cancer cells but the effect is more pronounced against HCT-116 cells
Summary
Cancer is as a result of the unregulated growth of cancer cells because it lost the normal regulatory mechanisms that control cell growth and become insensitive to growth inhibitory signals. The search for novel drug that can be used effectively for the unregulated growth of cancer cells has become a challenge. Chemotherapy is the most commonly used type of cancer treatment works by killing the fast-growing cancer cells or stopping the growth of cancer cells. Chemotherapy affects cancer cells, and could damage or slow the growth of healthy cells thereby causing side effects. Among common chemotherapies currently in use are [1] antimetabolites, work by interefering with metabolism of proliferating cells such as methotrexate and 5-fluorouracil; [2] alkylating agents, work by damaging DNA and result in death of growing cells such as cisplatin and carboplatin; and [3] mitosis inhibitors, work by targeting microtubules required in cell division such as taxol and paclitaxel.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
